- WuXi Biologics reported H1 2025 revenue of RMB9.95 billion ($1.37 billion), a 16% year-on-year increase.
- The company received EMA approval for its Ireland site and began construction on a modular drug product facility in Singapore.
WuXi Biologics, a global contract research, development and manufacturing organisation (CRDMO) headquartered in China, reported revenue of RMB9.95 billion ($1.37 billion) for the first half of 2025, marking a 16% increase compared with the same period in 2024.
The company said growth was driven by demand for antibody-drug conjugates (ADCs) and multi-specific antibodies, alongside greater utilisation of its global network of facilities. It highlighted the ramp-up of its Irish site as a key contributor.
The Dundalk, Ireland facility received European Medicines Agency (EMA) approval as a commercial manufacturing site for a client’s biologic. This marks the first commercial launch of a biologic from Ireland for WuXi Biologics. The site, which achieved full GMP clearance from the Irish Health Products Regulatory Authority in 2024, includes 6,000 litres of perfusion capacity and 48,000 litres of fed-batch capacity.
In parallel, WuXi Biologics announced in July that construction has started on a new modular drug product facility in Singapore. The 30,000-square-metre site is described by the company as one of the world’s largest modular biologics drug product facilities.
Under a strategic collaboration with Pharmadule Morimatsu, 470 modular components are being fabricated in Changshu City, China. These will be shipped to Singapore’s Tuas Biomedical Park for installation, with operations expected to begin in 2027.
